Show simple item record

dc.contributor.authorYood, Robert A.
dc.contributor.authorEmani, Srinivas
dc.contributor.authorReed, John I.
dc.contributor.authorLewis, Barbara Edelman
dc.contributor.authorCharpentier, Mary
dc.contributor.authorLydick, Eva
dc.date2022-08-11T08:09:22.000
dc.date.accessioned2022-08-23T16:28:03Z
dc.date.available2022-08-23T16:28:03Z
dc.date.issued2003-12-25
dc.date.submitted2011-12-09
dc.identifier.citationOsteoporos Int. 2003 Dec;14(12):965-8. Epub 2003 Sep 19. <a href="http://dx.doi.org/10.1007/s00198-003-1502-4">Link to article on publisher's site</a>
dc.identifier.issn0937-941X (Linking)
dc.identifier.doi10.1007/s00198-003-1502-4
dc.identifier.pmid14504697
dc.identifier.urihttp://hdl.handle.net/20.500.14038/36931
dc.description.abstractThere is little information available concerning compliance with pharmacologic therapy for osteoporosis in the usual care setting. We evaluated 176 consecutive, previously untreated women whose physicians initiated treatment for osteoporosis following a bone mineral density (BMD) test obtained as part of routine medical practice. All patients were contacted >/=1 year after the initial BMD test and offered a follow-up BMD. Compliance with therapy was defined as the percent of time that a patient filled a prescription for osteoporosis treatment. Ninety-three (53%) patients received estrogen (ERT), 93 (53%) bisphosphonates, 8 (5%) calcitonin, and 17 (10%) received more than one therapy. Ninety-one of the 176 (52%) agreed to a follow-up BMD at a mean of 590 days after the first study (participants); 85 declined a follow-up BMD (refusers). Participants and refusers were similar for age, treatment patterns, and compliance with therapy. For all patients, compliance for those given bisphosphonate was similar to those given ERT (70.7% (95% CI 63.5-77.9%) versus 69.2% (95% CI 61.7-76.8%). For participants, the change in spine BMD was similar for those treated with bisphosphonate [mean increase 3.53 (+/-2.64)%/year (mean+/-SD)] and those treated with ERT [mean increase 3.00 (+/-2.75)%/year]. For those participants whose compliance with therapy was >/=66%, the mean increase in spine bone density was 3.80 (+/-2.59)%/year compared to 2.11 (+/-2.64)%/year ( p<0.005) for those whose compliance was <66%. Compliance with ERT and bisphosphonate therapy initiated in routine practice after a BMD was similar over a mean of 590 days. Compliance less than 66% with drug treatment results in suboptimal improvement in bone density.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=14504697&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1007/s00198-003-1502-4
dc.subjectAged
dc.subjectAlendronate
dc.subjectBone Density
dc.subjectBone Density Conservation Agents
dc.subjectCalcitonin
dc.subjectEstrogens
dc.subjectEtidronic Acid
dc.subjectFemale
dc.subjectHip
dc.subjectHumans
dc.subjectLumbar Vertebrae
dc.subjectMiddle Aged
dc.subjectOsteoporosis, Postmenopausal
dc.subjectPatient Compliance
dc.subjectTreatment Outcome
dc.subjectHealth Services Research
dc.subjectPrimary Care
dc.titleCompliance with pharmacologic therapy for osteoporosis
dc.typeJournal Article
dc.source.journaltitleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
dc.source.volume14
dc.source.issue12
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/meyers_pp/312
dc.identifier.contextkey2396673
html.description.abstract<p>There is little information available concerning compliance with pharmacologic therapy for osteoporosis in the usual care setting. We evaluated 176 consecutive, previously untreated women whose physicians initiated treatment for osteoporosis following a bone mineral density (BMD) test obtained as part of routine medical practice. All patients were contacted >/=1 year after the initial BMD test and offered a follow-up BMD. Compliance with therapy was defined as the percent of time that a patient filled a prescription for osteoporosis treatment. Ninety-three (53%) patients received estrogen (ERT), 93 (53%) bisphosphonates, 8 (5%) calcitonin, and 17 (10%) received more than one therapy. Ninety-one of the 176 (52%) agreed to a follow-up BMD at a mean of 590 days after the first study (participants); 85 declined a follow-up BMD (refusers). Participants and refusers were similar for age, treatment patterns, and compliance with therapy. For all patients, compliance for those given bisphosphonate was similar to those given ERT (70.7% (95% CI 63.5-77.9%) versus 69.2% (95% CI 61.7-76.8%). For participants, the change in spine BMD was similar for those treated with bisphosphonate [mean increase 3.53 (+/-2.64)%/year (mean+/-SD)] and those treated with ERT [mean increase 3.00 (+/-2.75)%/year]. For those participants whose compliance with therapy was >/=66%, the mean increase in spine bone density was 3.80 (+/-2.59)%/year compared to 2.11 (+/-2.64)%/year ( p<0.005) for those whose compliance was <66%. Compliance with ERT and bisphosphonate therapy initiated in routine practice after a BMD was similar over a mean of 590 days. Compliance less than 66% with drug treatment results in suboptimal improvement in bone density.</p>
dc.identifier.submissionpathmeyers_pp/312
dc.contributor.departmentMeyers Primary Care Institute
dc.source.pages965-8


This item appears in the following Collection(s)

Show simple item record